PPARA and metabolic dysfunction-associated steatohepatitis: These have led to attempts to develop drugs that are selective (such as Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator) or target more than one type of PPAR receptor to develop synergy against NASH21–23; Elafibrinor a PPAR-α/δ agonist is currently in pivotal trials for NASH (NCT02704403).